Clinical applications of PET in oncology

CME Cancer Medicine

Volumn 1, Issue 2, 2002, Pages 48-55

  Ho Shon, Ivan A ^a   Maisey, M N ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Fluorodeoxyglucose; Oncology; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BONE MARROW METASTASIS; BRAIN TUMOR; BREAST CARCINOMA; CAMERA; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG MONITORING; DRUG RESPONSE; ESOPHAGUS CARCINOMA; EVIDENCE BASED MEDICINE; HEAD AND NECK CARCINOMA; HODGKIN DISEASE; HUMAN; LIFE EXPECTANCY; LIVER METASTASIS; LUNG CARCINOMA; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDIASTINUM MASS; MELANOMA; META ANALYSIS; NONHODGKIN LYMPHOMA; ONCOLOGY; POSITRON; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; STOMACH CARCINOMA; TESTIS CANCER; TREATMENT PLANNING;

EID: 0036936794     PISSN: 14758075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Marsden P, Sutcliffe-Goulden J. Principles and technology of PET scanning. Nuclear Medicine Communications 2000; 21:221-4.
2. Smith TA. FDG uptake, tumour characteristics and response to therapy: A review. Nuclear Medicine Communications 1998; 19: 97-105.
3. Warburg O. The Metabolism of Tumors. London: Constable, 1930; 129-69.
4. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. European Journal of Nuclear Medicine 1999; 26:1363-78.
5. O'Doherty MJ. PET in oncology I - Lung, breast, soft tissue sarcoma. Nuclear Medicine Communications 2000; 21:224-9.
6. Kubota K, Matsuzawa T, Fujiwara T, et al; Differential diagnosis of lung tumour with positron emission tomography: A prospective study. Journal of Nuclear Medicine 1990; 31: 1927-32.
7. Knight SB, Delbeke D, Stewart JR, et al; Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109: 982-8.
8. Dewan NA, Reeb SD, Gupta NC, et al; PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995; 108: 441-6.
9. Duhaylongsod FG, Lowe VJ, Patz EF, et al; Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). Journal of Thoracic & Cardiovascular Surgery 1995; 110: 130-9; discussion 139-40.
10. Bury T, Dowlati A, Paulus P, et al; Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. European Respiratory Journal 1996; 9: 410-4.
11. Gould MK, Maclean CC, Kuscher WG, et al; Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001; 285:914-24.
12. Lowe VJ, Naunheim KS. Current role of positron emission tomography in thoracic oncology. Thorax 1998; 53:703-12.
13. Coates G, Skehan SJ. Emerging role of PET in the diagnosis and staging of lung cancer. Canadian Respiratory Journal 1999; 6:145-52.
14. Erasmus JJ, McAdams HP, Patz EF, et al; Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR 1998; 170:1369-73.
15. Saunders CA, Dussek JE, O'Doherty MJ, et al; Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Annals of Thoracic Surgery 1999; 67: 790-7.
16. Love VJ, Fletcher JW, Gobar L, et al Prospective investigation of positron emission tomography in lung nodules. Journal of Clinical Oncology 1998; 16:1075-84.
17. Marom EM, Erasmus JJ, Patz EF. Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer 2000; 28:187-202.
18. Gambhir SS, Shepherd JE, Shah BD, et al; Analytical decision model for the cost-effective management of solitary pulmonary nodules. Journal of Clinical Oncology 1998; 16: 2113-25.
19. Dietlein M, Weber K, Gandjour A, et al; Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: A decision analysis based on cost reimbursement in Germany. European Journal of Nuclear Medicine 2000; 27: 1441-56.
20. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. American Review of Respiratory Disease 1990; 141: 1096-101.
21. Chin R Jr., Ward R, Reyes JW et al; Mediastinal staging of non-small-cell lung cancer with positron emission tomography. American Journal of Respiratory & Critical Care Medicine 1995; 152: 2090-6.
22. Wahl RL, Quint LE, Greenough RL, et al; Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation. Radiology 1994; 191: 371-7.
23. Valk PE, Pounds TR, Hopkins DM, et al; Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Annals of Thoracic Surgery 1995; 60: 1573-81; discussion 1581-2.
24. Sasaki M, Ichiya Y, Kuwabara Y, et al; The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography. European Journal of Nuclear Medicine 1996; 23: 741-7.
25. Sazon DA, Santiago SM, Soo Hoo GW, et al; Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. American Journal of Respiratory & Critical Care Medicine 1996; 153: 417-21.
26. Steinert HC, Hauser M, Allemann F, et al; Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-6.
27. Scott WJ, Gobar LS, Terry JD, et al; Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography. Journal of Thoracic & Cardiovascular Surgery 1996; 111: 642-8.
28. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000; 117: 773-8.
29. Pieterman RM, Van Putten JW, Meuzelaar JJ, et al; Preoperative staging of non-small-cell lung cancer with positron-emission tomography. New England Journal of Medicine 2000; 343: 254-61.
30. Gambhir SS, Hoh CK, Phelps ME, et al; Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. Journal of Nuclear Medicine 1996; 37: 1428-36.
31. Dietlein M, Weber K, Gandjour A, et al; Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: Priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27: 1598-609.
32. Ahuja V, Coleman RE, Herndon J, et al; The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-24.
33. Dhital K, Saunders CA, Seed PT, et al; [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. European Journal of Cardio-Thoracic Surgery 2000; 18: 425-8.
34. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al; Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. Journal of Clinical Oncology 1999; 17: 3201-6.
35. Nestle U, Walter K, Schmidt S, et al; 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. International Journal of Radiation Oncology, Biology, Physics 1999; 44: 593-7.
36. Kiffer JD, Berlangieri SU, Scott AM, et al; The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998; 19: 167-77.
37. Munley MT, Marks LB, Scarfone C, et al; Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects. Lung Cancer 1999; 23: 105-14.
38. Hebert ME, Lowe VJ, Hoffman JM, et al; Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings. American Journal of Clinical Oncology 1996; 19: 416-21.
39. Gupta NC, Falk PM, Frank AL, et al; Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebraska Medical Journal 1993; 78: 30-5.
40. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al; Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings. Radiology 1998; 206: 755-60.
41. Huebner RH, Park KC, Shepherd JE, et al; A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. Journal of Nuclear Medicine 2000; 41: 1177-89.
42. Valk PE, Abella-Columna E, Haseman MK, et al; Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Archives of Surgery 1999; 134: 503-11; discussion 511-3.
43. Vitola JV, Delbeke D, Sandler MP, et al; Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. American Journal of Surgery 1996; 171: 21-6.
44. Delbeke D, Vitola JV, Sandler MP, et al; Staging recurrent metastatic colorectal carcinoma with PET. Journal of Nuclear Medicine 1997; 38: 1196-201.
45. Delbeke D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. Journal of Nuclear Medicine 1999; 40: 591-603.
46. Schiepers C, Penninckx F, De Vadder N, et al; Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging. European Journal of Surgical Oncology 1995; 21: 517-22.
47. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al; Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography. Annals of Surgical Oncology 1997; 4: 613-20.
48. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al; Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Annals of Surgery 1998; 227: 319-23.
49. Beets G, Penninckx F, Schiepers C, et al; Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. British Journal of Surgery 1994; 81: 1666-70.
50. Valk PE, Pounds TR, Tesar RD, et al; Cost-effectiveness of PET imaging in clinical oncology. Nuclear Medicine & Biology 1996; 23: 737-43.
51. Park KC, Schwimmer J, Shepherd JE, et al; Decision analysis for the cost-effective management of recurrent colorectal cancer. Annals of Surgery 2001; 233: 310-9.
52. Rodriguez M, Rehn S, Ahlstrom H, et al; Predicting malignancy grade with PET in non-Hodgkin's lymphoma. Journal of Nuclear Medicine 1995; 36: 1790-6.
53. Lapela M, Leskinen S, Minn HR, et al; Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-7.
54. Bangerter M, Moog F, Buchmann I, et al; Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Annals of Oncology 1998; 9: 1117-22.
55. Partridge S, Timothy A, O'Doherty MJ, et al; 2-Flourine-18-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Annals of Oncology 2000; 11: 1273-1279.
56. Stumpe KD, Urbinelli M, Steinert HC, et al; Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. European Journal of Nuclear Medicine 1998; 25: 721-8.
57. Hoh CK, Glaspy J, Rosen P, et al; Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. Journal of Nuclear Medicine 1997; 38: 343-8.
58. Carr R, Barrington SF, Madan B, et al; Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-6.
59. Jerusalem G, Warland V, Najjar F, et al; Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nuclear Medicine Communications 1999; 20: 13-20.
60. Mikhaeel NG, Timothy A, M.J. OD, et al; 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leukaemia and Lymphoma 2000; 39: 543-553.
61. Jerusalem G, Beguin Y, Fassotte MF, et al; Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-33.
62. Romer W, Hanauske AR, Ziegler S, et al; Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-71.
63. Hoekstra OS, Ossenkoppele GJ, Golding R, et al; Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. Journal of Nuclear Medicine 1993; 34: 1706-10.
64. Hoekstra OS, Van Lingen A, Ossenkoppele GJ, et al; Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. European Journal of Nuclear Medicine 1993; 20: 1214-7.
65. Holder WD, Jr., White RL, Jr., Zuger JH, et al; Effectiveness of positron emission tomography for the detection of melanoma metastases. Annals of Surgery 1998; 227: 764-9, discussion 769-71.
66. Rinne D, Baum RP, Hor G, et al; Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71.
67. Damian DL, Fulham MJ, Thompson E, et al; Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Research 1996; 6: 325-9.
68. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. Journal of the American Academy of Dermatology 2000; 42: 606-11.
69. Wagner JD, Schauwecker D, Davidson D, et al; Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. Journal of Clinical Oncology 1999; 17: 1508-15.
70. Wahl RL, Helvie MA, Chang AE, et al; Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. Journal of Nuclear Medicine 1994; 35: 872-5.
71. Avril N, Dose J, Janicke F, et al; Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. Journal of Clinical Oncology 1996; 14: 1848-57.
72. Scheidhauer K, Scharl A, Pietrzyk U, et al; Qualitative [18F]FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability. European Journal of Nuclear Medicine 1996; 23: 618-23.
73. Noh DY, Yun IJ, Kim JS, et al; Diagnostic value of positron emission tomography for detecting breast cancer. World Journal of Surgery 1998; 22: 223-7; discussion 227-8.
74. Avril N, Dose J, Janicke F, et al; Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabelled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Journal of the National Cancer Institute 1996; 88: 1204-9.
75. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. European Journal of Nuclear Medicine 1996; 23: 1588-93.
76. Wahl RL, Cody RL, Hutchins GD, et al; Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabelled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-70.
77. Cook GJ, Houston S, Rubens R, et al; Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. Journal of Clinical Oncology 1998; 16: 3375-9.
78. Wahl RL, Zasadny K, Helvie M, et al; Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. Journal of Clinical Oncology 1993; 11: 2101-11.
79. Dehdashti F, Flanagan FL, Siegel BA. PET assessment of metabolic flare in advanced breast cancer. Radiology 1997; 205: 220.
80. Ahmad A, Barrington S, Maisey M, et al; Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. British Journal of Cancer 1999; 79: 478-482.
81. Leskinen-Kallio S, Nagren K, Lehikoinen P, et al; Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. British Journal of Cancer 1991; 64: 1121-4.
82. Dehdashti F, Mortimer JE, Siegel BA, et al; Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. Journal of Nuclear Medicine 1995; 36: 1766-74.
83. Wong WL, Chevretton EB, McGurk M, et al; A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clinical Otolaryngology & Allied Sciences 1997; 22: 209-14.
84. Adams S, Baum RP, Stuckensen T, et al; Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. European Journal of Nuclear Medicine 1998; 25: 1255-60.
85. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al; Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. Journal of Nuclear Medicine 1995; 36: 1747-57.
86. Hanasono MM, Kunda LD, Segall GM, et al; Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-5.
87. Wong WL, Hussain K, Chevretton E, et al; Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose head and neck images. American Journal of Surgery 1996; 172: 628-32.
88. Anzai Y, Carroll WR, Quint DJ, et al; Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200: 135-41.
89. Greven KM, Williams DW, 3rd, Keyes JW, Jr., et al; Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994; 74: 1355-9.
90. Deshmukh A, Scott JA, Palmer EL, et al; Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clinical Nuclear Medicine 1996; 21: 720-5.
91. Patronas NJ, Di Chiro G, Brooks RA, et al; Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-9.
92. Alavi JB, Alavi A, Chawluk J, et al; Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62: 1074-8.
93. Barker FG, 2nd, Chang SM, Valk PE, et al; 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79: 115-26.
94. Di Chiro G, DeLaPaz RL, Brooks RA, et al; Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-9.
95. Ogawa T, Inugami A, Hatazawa J, et al; Clinical positron emission tomography for brain tumors: Comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. Ajnr: American Journal of Neuroradiology 1996; 17: 345-53.
96. Francavilla TL, Miletich RS, Di Chiro G, et al; Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24: 1-5.
97. Pirotte B, Goldman S, Bidaut LM, et al; Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochirurgia 1995; 134: 79-82.
98. Flamen P, Lerut A, Van Cutsem E, et al; Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. Journal of Clinical Oncology 2000; 18: 3202-10.
99. Block MI, Patterson GA, Sundaresan RS, et al; Improvement in staging of esophageal cancer with the addition of positron emission tomography. Annals of Thoracic Surgery 1997; 64: 770-6; discussion 776-7.
100. Luketich JD, Schauer PR, Meltzer CC, et al; Role of positron emission tomography in staging esophageal cancer. Annals of Thoracic Surgery 1997; 64: 765-9.
101. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. British Journal of Cancer 1998; 78: 521-7.
102. Rankin SC, Taylor H, Cook GJ, et al; Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clinical Radiology 1998; 53: 659-65.
103. Lightdale CJ. Positron emission tomography: Another useful test for staging esophageal cancer. Journal of Clinical Oncology 2000; 18: 3199-201.
104. Hain SF, O'Doherty MJ, Timothy AR, et al; Fluorodeoxyglucose PET in the initial staging of germ cell tumours. European Journal of Nuclear Medicine 2000; 27: 590-4.
105. Hain SF, O'Doherty MJ, Timothy AR, et al; Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. British Journal of Cancer 2000; 83: 863-9.
106. Stephens AW, Gonin R, Hutchins GD, et al; Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. Journal of Clinical Oncology 1996; 14: 1637-41.
107. Nuutinen JM, Leskinen S, Elomaa I, et al; Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. European Journal of Cancer 1997; 33: 1234-41.
108. Ganjoo KN, Chan RJ, Sharma M, et al; Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. Journal of Clinical Oncology 1999; 17: 3457-60.
109. Cremerius U, Effert PJ, Adam G, et al; FDG PET for detection and therapy control of metastatic germ cell tumor. Journal of Nuclear Medicine 1998; 39: 815-822.
110. Adler LP, Blair HF, Williams RP, et al; Grading liposarcomas with PET using [18F]FDG. Journal of Computer Assisted Tomography 1990; 14: 960-2.
111. Adler LP, Blair HF, Makley JT, et al; Noninvasive grading of musculoskeletal tumors using PET. Journal of Nuclear Medicine 1991; 32: 1508-12.
112. Nieweg OE, Pruim J, Van Ginkel RJ, et al; Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. Journal of Nuclear Medicine 1996; 37; 257-61.
113. Kern KA, Brunetti A, Norton JA, et al; Metabolic imaging of human extremity musculoskeletal tumors by PET. Journal of Nuclear Medicine 1988; 29: 181-6.
114. Griffeth LK, Dehdashti F, McGuire AH, et al; PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182: 185-94.
115. Eary JF, Conrad EU, Bruckner JD, et al; Quantitative [F18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clinical Cancer Research 1998; 4: 1215-20.
116. Schulte M, Brecht-Krauss D, Heymer B, et al; Fluorodeoxyglucose positron emission tomography of soft tissue tumours: Is a non-invasive determination of biological activity possible? European Journal of Nuclear Medicine 1999; 26: 599-605.
117. Lucas JD, O'Doherty MJ, Cronin BF, et al; Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. British Journal of Surgery 1999; 86: 550-6.
118. Lucas JD, O'Doherty MJ, Wong JC, et al; Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. Journal of Bone & Joint Surgery - British Volume 1998; 80: 441-7.
119. Hain SF, O'Doherty MJ, Lucas JD, et al; Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nuclear Medicine Communications 1999; 20: 845-8.
120. Maisey MN, Wahl RL, Barrington SF. Atlas of Clinical Positron Emission Tomography. London: Arnold, 1999.